Literature DB >> 21229337

Antibiotic prophylaxis in pediatric urology: an update.

Saul P Greenfield1.   

Abstract

This article discusses the use of antibiotic prophylaxis in the treatment of three common conditions encountered by the pediatric urologist: 1) children with urinary infection and structurally and neurologically normal urinary tracts; 2) children with vesicoureteral reflux (VUR); and 3) children with prenatally diagnosed ureteropelvic and ureterovesical obstruction. The literature remains unclear and contradictory. Additional significant risk factors for recurrent infection are age, circumcision status in boys, and toileting function. The evidence for the use of prophylaxis is best in those with VUR, although not everyone with VUR must be on medication. In the absence of definitive evidence, the clinician must individualize the treatment of each patient and family.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21229337     DOI: 10.1007/s11934-010-0164-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  32 in total

Review 1.  Postnatal management of antenatal hydronephrosis.

Authors:  M Woodward; D Frank
Journal:  BJU Int       Date:  2002-01       Impact factor: 5.588

2.  Probiotics prophylaxis in children with persistent primary vesicoureteral reflux.

Authors:  Seung Joo Lee; Yoon Hee Shim; Su Jin Cho; Jung Won Lee
Journal:  Pediatr Nephrol       Date:  2007-05-26       Impact factor: 3.714

3.  Vesicoureteral reflux: the RIVUR study and the way forward.

Authors:  Saul P Greenfield; Russell W Chesney; Myra Carpenter; Marva Moxey-Mims; Leroy Nyberg; Alejandro Hoberman; Ron Keren; Ranjiv Matthews; Tej Mattoo
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

Review 4.  Antibiotic prophylaxis for children at risk of developing urinary tract infection: a systematic review.

Authors:  Rintaro Mori; Anita Fitzgerald; Craig Williams; Kjell Tullus; Kate Verrier-Jones; Monica Lakhanpaul
Journal:  Acta Paediatr       Date:  2009-07-22       Impact factor: 2.299

5.  The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children.

Authors:  W Farhat; D J Bägli; G Capolicchio; S O'Reilly; P A Merguerian; A Khoury; G A McLorie
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

Review 6.  Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children.

Authors:  Craig A Peters; Steven J Skoog; Billy S Arant; Hillary L Copp; Jack S Elder; R Guy Hudson; Antoine E Khoury; Armando J Lorenzo; Hans G Pohl; Ellen Shapiro; Warren T Snodgrass; Mireya Diaz
Journal:  J Urol       Date:  2010-07-21       Impact factor: 7.450

7.  The Swedish reflux trial in children: IV. Renal damage.

Authors:  Per Brandström; Tryggve Nevéus; Rune Sixt; Eira Stokland; Ulf Jodal; Sverker Hansson
Journal:  J Urol       Date:  2010-05-23       Impact factor: 7.450

8.  Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection.

Authors:  Joo Hoon Lee; Hyung Soon Choi; Jeong Kon Kim; Hye-Sung Won; Kun Suk Kim; Dae Hyuk Moon; Kyong-Sik Cho; Young Seo Park
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

Review 9.  Prevention of recurrent urinary tract infection in children.

Authors:  Gabrielle Williams; Jonathan C Craig
Journal:  Curr Opin Infect Dis       Date:  2009-02       Impact factor: 4.915

10.  An analysis of social and economic factors associated with followup of patients with vesicoureteral reflux.

Authors:  J Wan; S P Greenfield; M Talley; M Ng
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

View more
  2 in total

Review 1.  Long-term, low-dose prophylaxis against urinary tract infections in young children.

Authors:  Per Brandström; Sverker Hansson
Journal:  Pediatr Nephrol       Date:  2014-06-07       Impact factor: 3.714

2.  From Research Question to Conducting a Randomized Controlled Trial on Continuous Antibiotic Prophylaxis in Prenatal Hydronephrosis: A Rational Stepwise Process.

Authors:  Luis H Braga; Bethany Easterbrook; Kizanee Jegatheeswaran; Armando J Lorenzo
Journal:  Front Pediatr       Date:  2016-03-30       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.